Navigation Links
Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
Date:4/15/2009

n use, the shuttle is moved to one side by the patient to align one chamber of the shuttle with the mouth piece to allow the first inhalation, creating turbulence within the dose chamber and drawing the dry powder into the lung of the patient. The process is then repeated for the second dose chamber, as the shuttle is moved to the opposite side to permit another inhalation to take place. Visit http://www.hovione.com/twincaps.

Daiichi Sankyo has indicated that they are planning to file NDA in Japan in March 2010 and get approval within 2010, while Daiichi Sankyo and Biota are seeking licensees for the drug product collaboratively for the rest of world market. Hovione retains the right to commercialize TwinCaps(R) outside the field of influenza.

Peter Villax, Hovione's Vice President Pharma Business Unit stated "The unique design benefits of TwinCaps(R) including high dose capability, disposability and low cost are predicted to drive growth in Hovione's inhalation business and further leverage our already proven track record in developing inhalation APIs, formulation development and manufacturing services."

About Hovione. Hovione is an international company with 50 years' experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the US, China, Ireland and Portugal the company focuses on the most demanding customers, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit the Hovione site at http://www.hovione.com or contact Corporate Communications, Isabel Pina, +351-21-982-9362, e-mail: '/>"/>

SOURCE Hovione
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that ... Drug Administration (FDA) rare pediatric disease priority review voucher ... for alirocumab.  The priority review voucher entitles the holder ... for an expedited 6-month review from the filing date ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2
... ("Bioponic" or "the Company") (OTC: BPYT) today announced that ... to sales for the month,of January 2007., "We ... primarily,from continued success of our Flight Spray product. We ... an all-natural solution for,baby care marketed under the Gentle ...
... /Xinhua-PRNewswire/ -- China Shenghuo,Pharmaceutical Holdings, Inc. ("China ... in the research, development, manufacture, and,marketing of ... People,s Republic of China ("PRC"), today announced ... products in the United States during the,first ...
... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of ... received tentative approval from the U.S. Food,and Drug ... and 40 mg (base). Nexium(R) (Esomeprazole) is the,second ... annual market sales of,$5.5 billion (IMS -- MAT: ...
Cached Biology Technology:Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 3Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules 2
(Date:7/30/2014)... Helsinki and the Universitat Autnoma de Barcelona have been ... have taken millions of years to occur. Through small ... teeth, induced in the laboratory, scientists have obtained teeth ... the fossil registry of rodent species which separated from ... the development of their teeth, the team from the ...
(Date:7/30/2014)... to announce its new relationship with the International College ... will partner to publish International Journal of Neuropsychopharmacology ... , Alan Frazer, Editor-in-Chief of IJNP said, ... OUP will further facilitate the goal for the ... journals within neuropsychopharmacology. The conversion of the IJNP ...
(Date:7/30/2014)... has received a pledge of $1 million from the ... Laboratory,s new Neurobehavioral Biometry Center. , The ... enable the Laboratory to develop a greater breadth and ... goal of accelerating the pace of research to improve ... a premier resource for the Laboratory and its external ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... visual centers of men and women,s brains works is ... access journal Biology of Sex Differences . Men ... stimuli, but women are better at discriminating between colors. ... male sex hormone (androgen) receptors throughout cerebral cortex, especially ...
... for up to twelve weeks could dramatically improve the ... developed the new technology are presenting their work at ... University of Warwick. Researchers at the University of ... urinary bacteria, including most strains of Proteus bacteria ...
... proportion of HIV-infected patients in the U.S. receiving effective ... and HIV-infected patients appeared to be less infectious and ... study led by researchers at the Johns Hopkins Bloomberg ... the NA-ACCORD (North American AIDS Cohort Collaboration on Research ...
Cached Biology News:The eyes have it: Men do see things differently to women 2New long-term antimicrobial catheter developed 2HIV treatment use increases in the US 2
...
... high-throuput screening of a biological systems phenotype, ... changes in the expression levels of the ... studied, classified and compared to each other, ... a glance. Automatized scanning of the hybridized ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
RORgamma (S-14)...
Biology Products: